Head & Neck Cancers

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

The FDA has approved vandetanib for the treatment of unresectable, late-stage, metastatic medullary thyroid cancer

It has been more than half a century since radiation treatment was mistakenly deemed necessary to help infants with enlarged thymus glands avoid the risk of status lymphaticus and suffocation

New data suggest that office-based injection laryngoplasty (IL) appears to be a safe and effective treatment for laryngeal dysfunction in cancer patients.

New findings indicate that prereferral care does not conform to clinical practice guidelines in nearly half of patients with head and neck cancer who are referred to a tertiary care center with persistent or recurrent disease, new findings indicate.

Useful Online Resources and Clinical Trials for Head and Neck Cancers

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Everyone can benefit from good oral hygiene, but people with cancer need to pay particular attention to their dental health

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Useful Online Resources and Clinical Trials for Oral Cancer

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.

Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma

Identifying head and neck cancer patients who possess the FcyR genotype may help predict whether they will respond to monoclonal antibodies, which work by killing cancer cells bearing epidermal growth factor receptors (EGFR) on their surface.

Highlights from the 50th Annual Meeting of the American Society of Hematology.